Fulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

In this article:

Fulgent Genetics (NASDAQ:FLGT) Full Year 2023 Results

Key Financial Results

  • Revenue: US$289.2m (down 53% from FY 2022).

  • Net loss: US$167.8m (down by 217% from US$143.4m profit in FY 2022).

  • US$5.64 loss per share (down from US$4.77 profit in FY 2022).


All figures shown in the chart above are for the trailing 12 month (TTM) period

Fulgent Genetics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 175%.

Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 7.1% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Fulgent Genetics that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.